The FDA approved Kapvay (clonidine hydrochloride extended -release) as a monotherapy and adjunctive therapy for the treatment of attention- deficit/hyperactivity disorder in children and adolescents aged 6 to 17 years.
Caryn Belisle, RPh, Alka Patel, PharmD
Advertisement
Articles by Caryn Belisle, RPh, Alka Patel, PharmD
Advertisement
Latest Updated Articles
- Shionogi Pharma's Kapvay
Published: March 14th 2011 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Interchangeability Designation to Denosumab Biosimilars Stoboclo and Osenvelt
2
Denosumab Biosimilars Conexxence and Bomyntra Receive Interchangeability Designation
3
Because Ned Said: America’s Growing Pharmacy Deserts Are Leaving Patients High and Dry
4
Meeting Patients Where They Are: How Pharmacists Are Helping People Stay on Track With Schizophrenia Treatment
5
